Reducing the immunogenicity of CRISPR-Cas9 technology with Tregs

preview_player
Показать описание
Gene therapies based on CRISPR-Cas9 technology currently face issues relating to immunogenicity due to preexisting immunity to Cas9 proteins. Lena Peter, Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany, comments on promoting the immune tolerance of CRISPR-Cas9-based gene therapies. Gene therapies utilizing in vivo gene editing will particularly be affected as a result of T-cell mediated immune responses. However, Cas9-specific regulatory T cells (Tregs) can potentially ameliorate the immunogenic effects of effector T cells, and should be further investigated to guide decision making in clinical trials. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Lena Peter
  3. Institution: Berlin Institute of Health Center for Regenerative Therapies
  4. Event: ICLE 2022
  5. Format: Interview
  6. Subject: General
Рекомендации по теме
Reducing the immunogenicity 0:03:46

Reducing the immunogenicity of CRISPR-Cas9 technology with Tregs

CRISPRcon 2019 - 0:05:29

CRISPRcon 2019 - Gene editing to reduce gluten immunogenicity in wheat

[Technical Session] The 1:21:08

[Technical Session] The Future of Genome Editing Technology

Therapeutic Advances Using 1:14:33

Therapeutic Advances Using In Vivo CRISPR Genome Editing

Intellia’s Modular CRISPR/Cas9 1:04:42

Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

ESGCT e-Seminars: Intellia’s 1:05:35

ESGCT e-Seminars: Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease...

Zuben Sauna: Understanding 0:25:19

Zuben Sauna: Understanding and navigating the immune responses to CRISPR-associated nuclease Cas9

CRISPR-Cas9 in vivo 0:01:58

CRISPR-Cas9 in vivo gene editing: a new frontier

Limitations and solutions 0:04:16

Limitations and solutions associated with CRISPR technology

The Challenges Associated 0:03:07

The Challenges Associated With CRISPR Gene Editing

Nanoparticle Based Delivery 0:29:47

Nanoparticle Based Delivery of Gene Editing Enzymes

Scalable Manufacturing and 0:53:09

Scalable Manufacturing and Nanovesicle Delivery of CRISPR Cas9 Ribonucleoproteins Using a cGMP...

The advantages and 0:01:47

The advantages and applications of CRISPR-Cas 9

The Prevalence of 0:26:03

The Prevalence of Adaptive Immunity to Cas9 Proteins

Optimizing CD34+ Cell 0:59:49

Optimizing CD34+ Cell Genome Editing for Efficiency and HSPC Maintenance

CRISPR Cas9 is 0:08:08

CRISPR Cas9 is Dangerous

Benefits of an 0:07:12

Benefits of an all-in-one AAV CRISPR/Cas9 system for genome/epigenome editing

Phenotypic screening hit 0:41:08

Phenotypic screening hit target deconvolution using CRISPR/Cas9 screening technology | AAPS 2021

Precise and Efficient 0:52:47

Precise and Efficient Non-viral CRISPR Gene Editing Solutions for T Cell Engineering

CRISPR genome editing 0:57:13

CRISPR genome editing and its applications

Transplantation and Persistence 0:15:52

Transplantation and Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitors Cells

Use of CRISPR/Cas9 0:07:28

Use of CRISPR/Cas9 in CAR-T cell Therapy

Webinar: Lipid nanoparticle 0:09:39

Webinar: Lipid nanoparticle LNP application in gene editing therapies, CRISPR-Cas9

CRISPR/Cas9 edited T-cells 0:01:55

CRISPR/Cas9 edited T-cells in MM and sarcoma